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In South Africa HIV/AIDS is the top single cause of mortality,1-4 and 
the Free State province (FS) has the third highest HIV prevalence of 
the nine provinces, estimated to be 12.6% in 2008.5 There are few data 
on outcomes of patients from first contact with ART programmes, 
as most studies only report mortality from initiation of ART and 
ignore pre-treatment deaths.6 However, one study reported that 87% 
of deaths occurred in patients not on treatment.7 The Comprehensive 
HIV and AIDS Management (CHAM) Programme in the FS started 
in May 2004 as part of the scale-up of access to antiretroviral 
treatment (ART) in resource-limited settings.8 
Information on factors that influence whether an enrolled patient 
starts ART or dies before treatment, and the time spent waiting for 
ART, should inform policy aimed at reducing overall programme 
mortality. Although treatment programmes aim to start as many 
eligible patients as possible on treatment as quickly as possible,9 
shortages of staff and facilities, time taken for adherence training 
and diagnosis and treatment of opportunistic infections contribute to 
delays in initiating ART.10-12
We report on patient outcomes, including the proportion of 
patients who started treatment and deaths before and on treatment, 
at 1 year after enrolment in the FS public treatment programme to 
assess management of patients. We examined differences in outcomes 
according to facility and patient level characteristics. 
Methods
Setting and patients
All patients enrolled in the FS CHAM programme between May 
2004 and December 2007 were included if a CD4 value was available. 
After testing HIV positive in any FS clinic, patients were referred 
to nurse-run assessment facilities for initial assessment of eligibility 
for treatment, which includes a CD4 cell count measurement. 
Patients with CD4 cell counts >200 cells/µl were asked to return 
for another assessment after 6 - 12 months, or earlier if they 
experienced problems.13 Patients with a CD4 cell count of ≤200 
cells/µl, or with World Health Organization (WHO) disease stage 
IV (AIDS), were referred for treatment. Patients who start ART 
obtain monthly supplies of medication from assessment facilities and 
return to treatment facilities for review of their viral loads and repeat 
prescriptions 6-monthly. By the end of 2007, 30 clinics and 8 hospitals 
distributed over the 5 health districts of the FS were participating 
in the programme (Fig. 1). Two clinics were excluded because of 
delays in implementation of the electronic data collection system; 
of the remaining 28, 17 were assessment-only facilities and 11 were 
combined assessment and treatment facilities. Seven of the hospitals 
provide treatment for patients from assessment facilities, the 8th 
hospital functioning as a specialist referral facility for the province. 
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Objective. To assess differences in access to antiretroviral treatment 
(ART) and patient outcomes across public sector treatment facilities 
in the Free State province, South Africa.
Design. Prospective cohort study with retrospective database 
linkage. We analysed data on patients enrolled in the treatment 
programme across 36 facilities between May 2004 and December 
2007, and assessed percentage initiating ART and percentage 
dead at 1 year after enrolment. Multivariable logistic regression 
was used to estimate associations of facility-level and patient-level 
characteristics with both mortality and treatment status.
Results. Of 44 866 patients enrolled, 15 219 initiated treatment 
within 1 year; 8 778 died within 1 year, 7 286 before accessing 
ART. Outcomes at 1 year varied greatly across facilities and 
more variability was explained by facility-level factors than by 
patient-level factors. The odds of starting treatment within 1 year 
improved over calendar time. Patients enrolled in facilities with 
treatment initiation available on site had higher odds of starting 
treatment and lower odds of death at 1 year compared with those 
enrolled in facilities that did not offer treatment initiation. Patients 
were less likely to start treatment if they were male, severely 
immunosuppressed (CD4 count ≤50 cells/µl), or underweight 
(<50 kg). Men were also more likely to die in the first year after 
enrolment.
Conclusions. Although increasing numbers of patients started 
ART between 2004 and 2007, many patients died before accessing 
ART. Patient outcomes could be improved by decentralisation 
of treatment services, fast-tracking the most immunodeficient 
patients and improving access, especially for men. 
S Afr Med J 2010; 100: 675-681b.
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Data collection
Routine clinical information on patients from clinician notes on 
standardised forms was entered into the FS electronic medical 
record (EMR) system by trained data capturers and downloaded and 
imported into a data warehouse weekly. During this time, Meditech 
SATM was gradually implemented as the EMR system across the 
facilities.14 As each patient has a unique identifier within Meditech, 
they can be tracked across facilities within the province. Mortality 
is ascertained by monthly linkage (using national identity numbers) 
with the national death register, which is estimated to capture more 
than 90% of adult deaths in South Africa.15 Patient demographic and 
clinical characteristics extracted from Meditech included gender, age, 
weight and CD4 count nearest to enrolment and year of enrolment 
into the programme. The Meditech database was linked with the 
National Health Laboratory Services (NHLS) database to obtain CD4 
measurements to ensure that data were as complete as possible. The 
FS Department of Health gave permission for the data to be analysed, 
and the Human Research Ethics Committee of the University of 
Cape Town approved the protocol. No individual patient consent was 
deemed necessary as data were collected routinely for the CHAM 
programme, and no patient identifiers were included in the extracts 
used for analyses.
Information was obtained from programme staff on the type of 
facility (assessment-only clinic, treatment hospital or combined 
assessment and treatment clinic), location (rural/peri-urban/urban), 
health district, and distance between the facility and the point of 
care for initiation of ART (in kilometres). Data on staffing levels 
were obtained from the FS Human Resources database and included 
patient load, number of staff per 1 000 patients and number of staff 
vacancies per 1 000 patients. Staff per patient was calculated as the 
mean number of staff in each clinic over the period April 2005 - 
September 2008 divided by total number of patients enrolled in that 
clinic.
Outcomes
Patients were followed up to 31 December 2008, and all patients 
therefore potentially had at least 1 year of follow-up time. The 
outcomes of interest were whether the patient had initiated treatment 
or died in the first year after enrolment. 
Statistical analysis
We tabulated the characteristics of each facility and examined 
completeness of recording and variation in patient characteristics 
across facilities. We estimated median waiting times for treatment 
and mortality and assessed outcomes at 1 year after enrolment, by 
district, facility location, distance to ART initiation site and year of 
enrolment.
We used a mixed-effects logistic regression with random intercepts 
for facilities to estimate the odds of the patient starting treatment 
or dying within 1 year of enrolment, allowing for between-facility 
variability. Patient-level characteristics included in the model were 
gender, age, weight, CD4 count and year of enrolment. Year of 
enrolment was categorised as 2004/05, 2006 and 2007, as 2004 
and 2005 were similar in terms of patient outcomes. Facility-level 
characteristics included in the model were staffing per 1 000 patients, 
location and distance to ART initiation site. Location was categorised 
as rural or urban/peri-urban and included in the model as a binary 
variable. We fitted a sequence of four models to the data to assess 
the variation explained by facility- and patient-level characteristics: 
(i) the null model with no covariates; (ii) including patient-level 
characteristics only; (iii) including facility-level characteristics only; 
and (iv) including both facility- and patient-level characteristics. We 
examined the reduction in the standard deviation of the random 
effects distribution in each of these models.
Weight, age and CD4 count had missing values, which were 
imputed using the multivariate imputation by chained equations 
method in StataTM assuming that data were missing at random.16,17 
The imputation model consisted of all variables in the analysis model, 
including outcomes of interest, time to outcomes and other recorded 
values of pre-treatment weight and CD4. Distributions of imputed 
data were comparable with observed data. Data were more likely to be 
missing in urban facilities and facilities where treatment was available 
on the same site. Given that we identified predictors of missingness, 
it is not plausible that data were missing completely at random 
(MCAR). It is not possible to distinguish whether data were missing 
at random (MAR) or missing not at random (MNAR), but the fact 
that predictors of missingness tended to be clinic rather than patient 
characteristics makes the MAR assumption underlying the multiple 
imputation analyses more plausible. We analysed 25 datasets in which 
missing values were replaced by imputed values. Point estimates and 
standard errors (SEs) were calculated using Rubin’s rules.18 Analyses 
using imputed data are presented in the main paper and analyses 
restricted to complete case data are presented in Appendix 2.19 All 
analyses were performed using Stata statistical software.20
Results
Table I shows the characteristics of each health district in the 
programme, and characteristics of each facility are given in Appendix 
1 (Appendix 1 appears in the web version of this article only). The 
Motheo district includes mostly urban facilities and had the largest 
number of patients enrolled, while Xhariep had only rural facilities 
and had the smallest number of patients. Fig. 1 shows the location of 
each district within the province, together with the major towns in 
each district and locations of facilities. 
Table II shows the variability in completeness of data according to 
district, location and distance from treatment site. Completeness of 
weight records was the most variable, ranging from 16.2% to 94.1% 
recorded; these records were most complete in urban facilities. Rural 
facilities had the most complete recording of CD4 counts and peri-
urban facilities had the most complete ID recording. Facilities with 
ART initiation on site had the least complete CD4 records.
Between 2004 and 2007, 44 866 treatment-naïve patients aged 15 
years or over were enrolled across the 36 facilities. As reported in 
Appendix 1, the median CD4 cell count at enrolment was 170 cells/
µl and ranged across facilities from 98 to 255 cells/µl. Sixty-seven per 
cent of patients were female (range 54 - 76% across facilities), mean 
age at enrolment was 36 years (range 33 - 38 years), and mean weight 
was 57.6 kg (range 54.7 - 59.7 kg). Data were missing for age in 22 
patients (0.05%), for weight in 15 550 patients (34.7%) and for CD4 
count in 11 650 patients (26.0%).
Table III shows patient outcomes by district, distance to ART 
initiation site, location and year of enrolment. Xhariep had the lowest 
pre-ART mortality (13.6%) and the highest median CD4 cell count 
at enrolment (211 cells/µl). In contrast, Thabo Mofutsanyane had 
the highest pre-ART mortality (19.2%) and the lowest median CD4 
count (151 cells/µl). Fezile Dabi had the highest percentage initiated 
on ART (48.4%), and for those who initiated, had the shortest 
median waiting time for treatment (1.65 months). Despite having 
major urban centres, Motheo district had the longest waiting times 
for treatment (3.70 months). Over all clinics, percentage initiated on 
ART ranged from 7.9% to 82.2%, and mortality ranged from 8.1% 
to 32.8%. For those who were treated, median waiting times ranged 
from 1 day (in a hospital setting) to 5.4 months. Of all deaths 83% 
occurred in patients not receiving ART.
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Compared with assessment-only facilities, facilities where ART 
was available on site performed well in terms of proportion of 
patients who started treatment, except for those in Xhariep district, 
where there was no doctor for several months. Xhariep has only 
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rural clinics, and all but one of these were combined assessment and 
treatment facilities served by sessional doctors. Rural facilities had 
higher median CD4 counts at enrolment than peri-urban or urban 
facilities. Treatment hospitals had lower median CD4 counts, were 
mostly in urban areas and served sicker patients.
Table IV shows mutually adjusted odds ratios (ORs) for the 
association of facility- and patient-level characteristics with (i) 
starting treatment and (ii) death within 1 year of enrolment. As type 
of facility was strongly related to distance to ART initiation site, we 
were not able to assess the effect of both variables. Similarly, staffing 
levels, patient load and vacant posts were all strongly related to each 
other and independent effects of these variables cannot be assessed. 
We chose to include the distance to ART initiation site, and staffing 
levels, in our models. The odds of initiating treatment declined 
with increasing distance to ART initiation site (p-value for trend 
<0.001). Patients enrolled in facilities where ART was not available 
on the same site were more likely to die (OR 1.55, 95% confidence 
interval (CI) 1.28 - 1.89) compared with those enrolled in facilities 
where ART was available on site. Men were less likely to have started 
treatment (OR 0.67, 95% CI 0.64 - 0.71) and were more likely to 
have died within 1 year of enrolment (OR 1.30, 95% CI 1.23 - 1.37). 
Compared with older patients, those aged 15 - 29 years had lower 
odds of starting treatment (OR 0.80, 95% CI 0.75 - 0.85). The odds 
of starting treatment increased with weight and with CD4 count up 
to the threshold of 200 cells/µl. The odds of dying within 1 year of 
enrolment increased with age and decreased with weight and CD4 
count. Patients enrolled in 2007 were more likely to start treatment 
than those enrolling in earlier years. 
In the complete case analyses (N=24 510, reported in Appendix 2 – 
web version only), the association of staffing levels with the odds of 
starting treatment was attenuated and the associations of location, 
distance from ART initiation site and CD4 were strengthened. 
The association of year of enrolment with the odds of dying were 
strengthened. In the imputed data, weight had a median of 56.5 kg 
(interquartile range (IQR) 49.0 - 65.4), compared with 56 kg (IQR 
49.0 - 64.0) in the complete case data. CD4 had a median of 173 cells/
µl (IQR 80 - 316) in imputed data compared with 170 cells/µl (IQR 
76 - 318) in complete case data.
Table III. Patient outcomes at 1 year after enrolment by district, facility type, location and year of enrolment
    N
Median 
CD4 N (%) dead
N (%) dead 
before initiating 
treatment
N (%) 
treated
Median 
waiting time  
to treatment 
(mo.)
Median time 
to death for 
those who 
died (mo.)
Overall 44 866  170   8 778 (19.6)     7 286 (16.2) 15 219 (33.9)       2.7      3.0
Patients who were eligible at 
enrolment
19 120  90   5 130 (26.8)     4 047 (21.2) 10 194 (53.3)       2.98      3.34
Patients who were not eligible at 
enrolment
14 096  350   878 (6.2)     799 (5.7) 1 704 (12.1)       3.54      5.55
Patients with unrecorded CD4 
at enrolment
11 650  NA   2 770 (23.8)     2 440 (20.9) 3 321 (28.5)       1.49      1.79
District
Fezile Dabi 5 644  154   1 072 (19.0)     829 (14.7) 2 731 (48.4)       1.65      2.74
Lejweleputswa 8 112  166   1 642 (20.2)     1 287 (15.9) 3 210 (39.6)       2.74      3.27
Motheo 15 477  188   2 648 (17.1)     2 368 (15.3) 4 084 (26.4)       3.70      3.17
Thabo Mofutsanyane 12 108  151   2 813 (23.2)     2 322 (19.2) 4 191 (34.6)       2.38      2.94
Xhariep 3 525  211   603 (17.1)     480 (13.6) 1 003 (28.5)       2.84      3.17
Distance from treatment site
Same site 12 959  167   1 931 (14.9)     1 445 (11.2) 5 364 (41.4)       2.05      3.04
≤8 km 12 653  160   2 675 (21.1)     2 136 (16.9)   5 005 (39.6)       2.58      2.98
9 - 15 km 13 558  176   3 107 (22.9)     2 794 (20.6) 3 382 (24.9)       3.90      3.31
>15 km 5 696  186   1 065 (18.7)     911 (16.0) 1 468 (25.8)       2.61      2.61
Location
Urban 3 394  105   714 (21.0)     474 (14.0) 2 316 (68.2)       1.42      3.04
Peri-urban 31 477  173   6 338 (20.1)     5 431 (17.3) 9 702 (30.8)       3.07      3.17
Rural 9 995  188   1 726 (17.3)     1 381 (13.8) 3 201 (32.0)       2.28      2.74
Year of enrolment
2004 6 567  168   1 260 (19.2)     1 117 (17.0) 1 748 (26.6)       4.50      4.23
2005 10 872  184   2 273 (20.9)     2 005 (18.4) 2 708 (24.9)       3.83      3.47
2006 12 877  185   2 485 (19.3)     2 072 (16.1) 4 259 (33.1)       2.68      2.91
2007 14 550  147   2 760 (19.0)     2 092 (14.4) 6 504 (44.7)       1.95      2.31
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Most of the variation across facilities in the odds of starting 
treatment was explained by facility- rather than patient-
level characteristics. In the null model for starting treatment, 
facility level standard deviation (SD) was 1.58 (95% CI 1.33 - 
2.08); this fell to 1.46 (95% CI 1.26 - 1.83) when patient-level 
characteristics were added and to 1.22 (95% CI 1.13 - 1.38) when 
facility-level characteristics were added. Including both patient- and 
facility-level variables resulted in an SD of 1.19 (95% CI 1.11 - 1.33). 
Discussion
Main findings 
We found a large amount of variation in odds of starting treatment 
across facilities and that differences in facility-level characteristics, 
rather than patient population, appear to drive this variation. Overall, 
by the end of 2008 around 34% of adults in the FS public sector 
programme received ART within 1 year of enrolment. The odds of 
starting treatment within 1 year increased between 2004 and 2007. 
However, large numbers of patients continue to die, most deaths (83%) 
occurring in patients not receiving ART. Patients who were eligible at 
enrolment and started ART waited a median of almost 3 months 
before starting treatment. Patients were less likely to start treatment 
within 1 year if they were male, severely immunosuppressed (CD4 
≤50 cells/µl), underweight (<50 kg), or sought care from a facility 
where ART initiation was more than 15 km away. Men and patients 
enrolled at facilities where treatment could not be initiated were also 
more likely to die in the first year after enrolment. 
Strengths and limitations 
This cohort is one of few studies to report on outcomes after 
enrolment in HIV care and not just from treatment initiation.9,21,22 A 
strength is that it is a large cohort, representative of the HIV-infected 
population based on routinely collected data in the FS, where there is 
an established data capture system in place with mechanisms to follow 
up specific data queries in each clinic. National identity numbers 
have been documented for a large proportion of patients and regular 
linkage with the national death register means that ascertainment of 
death is fairly complete, even in those lost to the programme. In an 
earlier study using the FS data, only 20% of all deaths were recorded 
in the medical records,7 which emphasises the importance of linking 
to the national death register. 
A limitation is the large number of patients with missing weight and 
CD4 measurements. Although CD4 measurements were routinely 
taken on almost all patients, the database recorded them on only half 
of the patients in the cohort. This was improved to three-quarters of 
the patients by linkage using deterministic matching with records of 
blood results obtained from the NHLS. 
Comparison with other studies 
We are not aware of any studies that have been able to consider 
these outcomes across a range of facilities as we have done. Three 
South African studies showed high mortality rates in patients who 
had not initiated ART.9,21,23 Our finding that facilities with shorter 
delays had lower mortality supports their conclusions that mortality 
could be reduced by minimising unnecessary in-programme delays 
in treatment initiation. A simulation exercise24 also concluded 
that prioritising those with the lowest CD4 counts should improve 
outcomes. A cohort in Durban, which is well resourced by funding 
from non-governmental organisations,23 reported that 55% of ART-
eligible patients had started treatment within 1 year of diagnosis. The 
FS CHAM programme appears to perform similarly, as 53% of known 
ART-eligible patients started treatment within 1 year of enrolment. 
South Africa faces unique challenges in the roll-out of public sector 
ART.25 While most deaths were in untreated patients, our study 
does not directly show the effect of ART in reducing mortality. A 
KwaZulu-Natal study estimates that standardised mortality rates 
declined with a rate ratio of 0.78 for women and 0.71 for men after 
scale-up of public sector ART.26 
Generalisability 
Our results may be generalisable to patients enrolling in care in 
similar settings, but cannot be applied to the population that is 
HIV-infected and not seeking care. We showed large differences in 
outcomes between facilities, which have implications for how HIV 
programmes are monitored. HIV prevalence is commonly monitored 
through sentinel surveillance, and specific research questions are 
often addressed using sentinel sites.27 However, sentinel sites may 
over-represent urban settings and not be representative of the general 
population.28 Care should be taken when evaluating programmes 
based on these data.
Policy implications 
Patients who are assessed in one facility, but have to attend another 
to initiate ART, are disadvantaged compared with those who attend 
combined assessment and treatment facilities for all their care. This 
suggests that assessment-only facilities should be enabled to provide 
treatment or to ensure prompt referrals to treatment facilities. The 
referral process is one example of a barrier to accessing care. Drug-
readiness training may be another barrier, as it can be protracted. 
Distance to appropriate facilities and transport costs may also be a 
barrier to access, particularly in rural locations. It is not always clinic 
practices that lead to delayed uptake of ART. In 2008, the FS had 
the lowest ART coverage of all South African provinces, estimated 
at 25.8%, which is probably due to the large proportion of eligible 
patients who are unaware of their HIV status.29 The 2005 Human 
Sciences Research Council household survey found that only 36% 
of HIV-infected adults had ever been tested for HIV.30 Lack of 
awareness of HIV status contributes to the delayed uptake of ART, 
and campaigns should continue to target people who are unaware of 
their status. 
Many of the sickest patients in our cohort died before they could 
initiate treatment, which demonstrates the need to fast-track the 
most at-risk patients. Fast-tracking would be easier to implement 
if treatment initiation were offered at assessment facilities, which is 
increasingly the case. This is being achieved through sessional visits 
by treatment facility doctors, and the STRETCH (Streamlining Tasks 
and Roles to Expand Treatment and Care for HIV) intervention 
currently under evaluation in a pragmatic randomised controlled 
trial in the FS. This intervention aims to optimise the use of scarce 
clinical skills by allowing designated nurses to re-prescribe and 
Fig. 1. Map of the Free State province ART facilities
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initiate treatment in selected adults, thereby freeing up doctors to 
see sicker patients. The trial seeks to provide evidence that a triaged 
system, where nurses are supported to prescribe ART using clearly 
defined clinical protocols, will improve outcomes in this setting.31 
Our findings support evidence that men are disadvantaged in terms 
of treatment access. Postulation that women may be disadvantaged in 
access to health care because of familial and child-rearing duties32 
resulted in many services focusing on women. Services for women 
are more developed through the need for antenatal and child health 
clinics. However, health-seeking behaviours between genders are 
known to differ, with men less likely to access services they need.33 
Stigma, work responsibilities and homophobia might also make 
it more difficult for men to accept an HIV diagnosis and to seek 
treatment.33 Studies from similar resource-poor settings emphasise 
the need to encourage men to seek care earlier in HIV disease and to 
start ART, and suggest that health services to specifically address the 
needs of men should be developed.34-36
This study was funded by the National Institute of Allergy and Infectious 
Diseases (NIAID, grant 1 U01 AI069924-01). Suzanne Ingle was funded 
by a UK Medical Research Council PhD Studentship and Margaret May 
was funded by UK Medical Research Council grant GO600599. The FS 
Table IV. Adjusted associations of facility- and patient-level characteristics with patient outcomes 1 year post enrolment, using 25 
imputed datasets (odds ratios are from logistic regression analyses adjusted for all variables in the table and including facility as a 
random effect)  
         Outcome at 1 year 
                Patient started treatment     Patient died
     N* OR (95% CI) p-value  OR (95% CI) p-value
Facility-level characteristics
Average staff (per 1 000 patients)
<1.5     16 472 0.37 (0.17 - 0.79) 0.010  1.06 (0.80 - 1.41) 0.670
1.5 - 2.5     14 274 1 (baseline)   1 (baseline)
>2.5     14 120 1.22 (0.61 - 2.43) 0.580  1.07 (0.83 - 1.39) 0.611
Location 
Rural     9 995 0.71 (0.42 - 1.20) 0.206  1.02 (0.81 - 1.29) 0.848
Urban/peri-urban    34 871 1 (baseline)   1 (baseline)
Distance to treatment initiation site
Same site    12 959 1 (baseline)   1 (baseline)
≤8 km     12 653 0.67 (0.35 - 1.30) 0.239  1.51 (1.16 - 1.95) 0.002
9 - 15 km    13 558 0.48 (0.20 - 1.16) 0.105  1.88 (1.35 - 2.61) <0.001
>15 km     5 696 0.35 (0.19 - 0.64) 0.001  1.53 (1.18 - 1.98) 0.001
Patient-level characteristics
Gender
Male     14 953 0.67 (0.64 - 0.71) <0.001  1.30 (1.23 - 1.37) <0.001
Female     29 913 1 (baseline)   1 (baseline)
Age (years)
15 - 29     12 739 0.80 (0.75 - 0.85) <0.001  0.72 (0.67 - 0.77) <0.001
30 - 39     18 114 1 (baseline)   1 (baseline)
40 - 49     10 234 1.04 (0.98 - 1.10) 0.236  1.07 (1.00 - 1.14) 0.036
≥50     3 779 0.99 (0.90 - 1.07) 0.737  1.33 (1.22 - 1.46) <0.001
Weight (kg)
<40     2 619 0.55 (0.48 - 0.62) <0.001  2.60 (2.30 - 2.95) <0.001
40 - 49     9 500 0.82 (0.76 - 0.88) <0.001  1.55 (1.43 - 1.67) <0.001
50 - 59     14 560 1 (baseline)   1 (baseline)
60 - 79     15 420 1.05 (0.99 - 1.12) 0.118  0.69 (0.64 - 0.75) <0.001
≥80     2 767 1.21 (1.07 - 1.37) 0.003  0.48 (0.40 - 0.57) <0.001
First pre-treatment CD4 count(cells/μl)
≤25     3 872 0.73 (0.67 - 0.80) <0.001  3.75 (3.41 - 4.12) <0.001
26 - 50     3 457 0.87 (0.80 - 0.96) 0.004  2.30 (2.08 - 2.54) <0.001
51 - 100     6 472 0.95 (0.89 - 1.03) 0.208  1.71 (1.58 - 1.85) <0.001
101 - 200    11 637 1 (baseline)   1 (baseline)
201 - 350    10 100 0.24 (0.22 - 0.26) <0.001  0.54 (0.50 - 0.60) <0.001
>350     9 328 0.05 (0.05 - 0.06) <0.001  0.25 (0.22 - 0.28) <0.001
Year of enrolment
2004/5     17 439 1 (baseline)   1 (baseline)
2006     12 877 1.23 (1.16 - 1.31) <0.001  0.99 (0.93 - 1.06) 0.788
2007     14 550 1.51 (1.42 - 1.60) <0.001  0.92 (0.86 - 0.99) 0.017
*Average over imputations.
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Appendix 1. Facility characteristics
Clinic N Location
Distance to 
treatment site 
(km)
Hospital or 
clinic
Staff per 
1 000 
patients
Vacancies 
per 1 000 
patients
Median 
CD4 at 
enrolment
District: Fezile Dabi
Boitumelo Hospital 531 U 0 H 12.17 8.69 120
Lesedi CHC 781 P 4 C 5.32 1.08 146
Metsimaholo Clinic 342 R 70 C 9.61 5.64 173
Metsimaholo Hospital 568 U 0 H 16.22 4.40 98.5
PAX CHC 185 R 0 C 23.70 22.59 180
Refengkgotso Clinic 656 R 40 C 4.46 3.34 226
Steynsrus Clinic 217 R 70 C 17.69 5.60 232
Zamdela CHC 2 364 P 8 C 1.73 0.44 146
District: Lejweleputswa
Bongani Hospital 448 U 0 H 23.97 11.43 115
Matjhabeng Clinic 2 693 P 7 C 1.80 0.41 167
Mohau Hospital 328 R 0 H 27.04 13.64 118
Phomolong Clinic 2 035 R 30 C 2.04 0.46 192
Welkom Clinic 2 608 P 15 C 1.60 0.51 165
District: Motheo
Batho Clinic 3  383 P 8 C 1.38 0.16 211
Botshabelo Hospital 267 P 0 H 29.27 16.76 123
Heidedal CHC 4 722 P 0 C 1.34 0.24 223
Jazzman Clinic 394 P 8 C 10.82 1.87 121.5
MUCPP CHC 4 593 P 12 C 1.28 0.20 217
National Hospital 794 U 0 H 11.57 5.31 99
Pelonomi Hospital 277 P 0 C 9.46 10.74 173
Winnie Mandela Clinic 1 047 P 5 C 3.72 1.06 129
District: Thabo Mofutsanyane
Bohlokong Clinic 1 991 P 4 C 1.94 0.58 143
Bophelong Clinic 339 R 0 C 13.82 17.08 176
Mamello CHC 392 R 0 C 12.29 16.65 114.5
Manapo Hospital 873 U 0 H 10.15 3.33 104
Namahadi Clinic 3 774 P 15 C 1.25 0.09 157
PhekolongHospital 180 U 0 H 48.68 18.86 100
Tseki Clinic 2 583 P 12 C 1.98 0.12 165
Tsiame B Clinic 1 976 R 25 C 2.60 0.16 163
District: Xhariep
Bophelong P’burg CHC 682 R 0 C 8.27 3.18 254.5
Ethembeni Clinic 905 R 0 C 4.16 4.55 209
Itumeleng Clinic 703 R 0 C 7.04 9.96 181
Lephoi Clinic 236 R 0 C 15.61 22.64 238.5
Matlakeng Clinic 182 R 0 C 22.56 38.75 164.5
Nelson Mandela Clinic 470 R 80 C 7.09 1.67 184
Thembalethu Clinic 347 R 0 C 12.89 18.81 214.5
   Total 44 866 4.27 2.26 170
R = rural; P = peri-urban; U = urban; H = hospital; C = clinic.
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Appendix 2. Adjusted associations of facility- and patient-level characteristics with patient outcomes at 1 year post enrolment: 
complete case analysis (N=24 510)  
Outcome at 1 year
          Patient started treatment Patient died
N     OR (95% CI) p-value OR (95% CI) p-value
Facility-level characteristics
Average staff (per 1 000 patients)
<1.5 8 068     0.41 (0.17 - 0.97) 0.044 0.84 (0.55 - 1.29) 0.429
1.5 - 2.5 9 211     1 (baseline) 1 (baseline)
>2.5 7 231     1.24 (0.57 - 2.71) 0.589 1.04 (0.69 - 1.56) 0.853
Location
Rural 6 245     0.57 (0.30 - 1.08) 0.084 1.30 (0.90 - 1.86) 0.158
Urban/peri-urban 18 265     1 (baseline) 1 (baseline)
Distance to treatment initiation site 0.001* 0.007*
Same site 5 513     1 (baseline) 1 (baseline)
≤8 km 7 660     0.54 (0.25 - 1.16) 0.113 1.63 (1.07 - 2.49) 0.023
9 - 15 km 7 803     0.42 (0.15 - 1.14) 0.088 2.10 (1.26 - 3.52) 0.005
>15 km 3 534     0.35 (0.18 - 0.71) 0.004 1.50 (1.03 - 2.18) 0.035
Patient-level characteristics
Gender
Male 7 869     0.70 (0.66 - 0.75) <0.001 1.36 (1.26 - 1.47) <0.001
Female 16 641     1 (baseline) 1 (baseline)
Age (yrs)
15 - 29 6 789     0.88 (0.81 - 0.95) 0.001 0.75 (0.68 - 0.83) <0.001
30 - 39 10 045     1 (baseline) 1 (baseline)
40 - 49 5 706     1.05 (0.97 - 1.14) 0.236 1.11 (1.01 - 1.21) 0.023
≥50 1 970     1.02 (0.91 - 1.15) 0.718 1.42 (1.25 - 1.61) <0.001
Weight (kg)
<40 1 116     0.58 (0.50 - 0.67) <0.001 3.18 (2.75 - 3.68) <0.001
40 - 49 5 484     0.80 (0.74 - 0.87) <0.001 1.61 (1.47 - 1.76) <0.001
50 - 59 8 533     1 (baseline) 1 (baseline)
60 - 79 7 737     1.11 (1.02 - 1.20) 0.010 0.68 (0.61 - 0.74) <0.001
≥80 1 640     1.11 (0.96 - 1.28) 0.173 0.53 (0.43 - 0.66) <0.001
First pre-treatment CD4 count(cells/μl)
≤25 2 279     0.57 (0.51 - 0.63) <0.001 4.29 (3.84 - 4.80) <0.001
26 - 50 1 913     0.71 (0.64 - 0.80) <0.001 2.34 (2.07 - 2.64) <0.001
51 - 100 3 451     0.88 (0.81 - 0.97) 0.007 1.75 (1.58 - 1.94) <0.001
101 - 200 6 255     1 (baseline) 1 (baseline)
201 - 350 5 356     0.15 (0.14 - 0.16) <0.001 0.52 (0.46 - 0.59) <0.001
>350 5 256 0.02 (0.02 - 0.03) <0.001 0.26 (0.22 - 0.30) <0.001
Year of enrolment
2004/5 12 026 1 (baseline) 1 (baseline)
2006 7 131 1.20 (1.11 - 1.30) <0.001 0.95 (0.87 - 1.04) 0.250
2007 5 353 1.76 (1.61 - 1.92) <0.001 0.85 (0.76 - 0.94) 0.002
*p for trend.
OR = odds ratio from logistic regression analyses adjusted for all variables in the table and including facility as a random effect.
